Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Shares of Eli Lilly & Co. LLY rallied 2.89% to $798.89 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.78% to 6,358.91 ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer shed light on. While Cramer still backed the company, he did express uncertainty about its future as he stated: “What I’m thinking ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company ...

Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly & Co. closed 20.16% below its 52-week high of $972.53, which the company achieved on August 22nd.

Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...

David Mooney, who most recently served as Chief of Cyber Protective Services at the Cybersecurity and Infrastructure Security ...